BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20123529)

  • 1. [Prostate cancer management and factors associated with radical prostatectomy in France in 2001].
    Jegu J; Tretarre B; Velten M; Guizard AV; Danzon A; Buemi A; Colonna M; Kadi-Hanifi AM; Ganry O; Molinie F; Bara S; Rebillard X; Grosclaude P
    Prog Urol; 2010 Jan; 20(1):56-64. PubMed ID: 20123529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer of the prostate in France: results of the survey CCAFU-FRANCIM].
    SouliƩ M; Villers A; Grosclaude P; Menegoz F; Schaffer P; Mace-Lesec'h J; Sauvage-Machelard M; Molinier L; Grand A
    Prog Urol; 2001 Jun; 11(3):478-85. PubMed ID: 11512461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
    Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H
    J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial treatment patterns for clinically localized prostate cancer and factors associated with the treatment in Louisiana.
    Wu X; Chen VW; Andrews PA; Chen L; Ahmed MN; Schmidit B; Hsieh M; Fontham ET
    J La State Med Soc; 2005; 157(4):188-94. PubMed ID: 16250368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
    Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT
    J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
    Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
    Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
    J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.